Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Sarepta Therapeutics ( SRPT) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.0%. By the end of trading, Sarepta Therapeutics rose $0.58 (1.7%) to $35.51 on light volume. Throughout the day, 1,183,515 shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 2,026,500 shares. The stock ranged in a price between $33.99-$35.70 after having opened the day at $34.81 as compared to the previous trading day's close of $34.93. Other companies within the Drugs industry that increased today were: Aegerion Pharmaceuticals ( AEGR), up 31.4%, Halozyme Therapeutics ( HALO), up 18.4%, Tesaro ( TSRO), up 14.1% and Prothena Corporation ( PRTA), up 13.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Sarepta Therapeutics has a market cap of $1.1 billion and is part of the health care sector. Shares are up 36.1% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Sarepta Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share.

On the negative front, Biota Pharmaceuticals ( BOTA), down 66.5%, Oncothyreon ( ONTY), down 24.5%, Infinity Pharmaceuticals ( INFI), down 22.6% and Idera Pharmaceuticals ( IDRA), down 16.2% , were all laggards within the drugs industry with Alexion Pharmaceuticals ( ALXN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

null

More from Markets

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit